These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34662688)

  • 21. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
    Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Midregional-proAtrial Natriuretic Peptide and High Sensitive Troponin T Strongly Predict Adverse Outcome in Patients Undergoing Percutaneous Repair of Mitral Valve Regurgitation.
    Wöhrle J; Karakas M; Trepte U; Seeger J; Gonska B; Koenig W; Rottbauer W
    PLoS One; 2015; 10(9):e0137464. PubMed ID: 26368980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mid-regional pro-atrial natriuretic peptide levels before and after hemodialysis predict long-term prognosis.
    Hasselbalch RB; Kristensen JH; Nielsen TL; Plesner LL; Rydahl C; Schou M; Goetze JP; Bundgaard H; Iversen KK
    Clin Biochem; 2021 Aug; 94():20-26. PubMed ID: 33865815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diastolic orthostatic hypertension and cardiovascular prognosis in type 2 diabetes: a prospective cohort study.
    Wijkman M; Länne T; Östgren CJ; Nystrom FH
    Cardiovasc Diabetol; 2016 Jun; 15():83. PubMed ID: 27255168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
    Bégué C; Mörner S; Brito D; Hengstenberg C; Cleland JGF; Arbustini E; Galve E; Wichter T; Richter A; Golmard JL; Bernard M; Dubourg O; Komajda M; Charron P; Isnard R
    Heart; 2020 Feb; 106(3):196-202. PubMed ID: 31350276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD.
    Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M
    Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249
    [No Abstract]   [Full Text] [Related]  

  • 28. B-type natriuretic peptide for prediction of incident clinically significant abdominal aortic aneurysm: A population-based prospective study.
    Acosta S; Gottsäter A; Engström G; Melander O; Zarrouk M; Nilsson PM; Smith JG
    Vasc Med; 2018 Feb; 23(1):46-51. PubMed ID: 29343179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum leptin levels are independently related to the incidence of ischemic heart disease in a prospective study of patients with type 2 diabetes.
    Vavruch C; Länne T; Fredrikson M; Lindström T; Östgren CJ; Nystrom FH
    Cardiovasc Diabetol; 2015 May; 14():62. PubMed ID: 25994184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of midregional pro-A-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease followed over 8 years.
    Karakas M; Jaensch A; Breitling LP; Brenner H; Koenig W; Rothenbacher D
    Clin Chem; 2014 Nov; 60(11):1441-9. PubMed ID: 25139456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study.
    Xanthakis V; Enserro DM; Murabito JM; Polak JF; Wollert KC; Januzzi JL; Wang TJ; Tofler G; Vasan RS
    Circulation; 2014 Nov; 130(19):1676-83. PubMed ID: 25274000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma natriuretic peptides and incidence of subtypes of ischemic stroke.
    Berntsson J; Zia E; Borné Y; Melander O; Hedblad B; Engström G
    Cerebrovasc Dis; 2014; 37(6):444-50. PubMed ID: 25060145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The natriuretic peptide MR-proANP predicts all-cause mortality and adverse outcome in community patients: a 10-year follow-up study.
    Odermatt J; Hersberger L; Bolliger R; Graedel L; Christ-Crain M; Briel M; Bucher HC; Mueller B; Schuetz P
    Clin Chem Lab Med; 2017 Aug; 55(9):1407-1416. PubMed ID: 28107168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; Dhillon O; Kelly D; Squire IB; Struck J; Quinn P; Morgenthaler NG; Bergmann A; Davies JE; Ng LL
    J Am Coll Cardiol; 2008 May; 51(19):1857-64. PubMed ID: 18466800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients.
    Yagmur E; Sckaer JH; Koek GH; Weiskirchen R; Trautwein C; Koch A; Tacke F
    J Transl Med; 2019 Dec; 17(1):415. PubMed ID: 31830996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes.
    Jensen J; Schou M; Kistorp C; Faber J; Hansen TW; Jensen MT; Andersen HU; Rossing P; Vilsbøll T; Jørgensen PG
    Diabetes Obes Metab; 2019 Mar; 21(3):736-740. PubMed ID: 30447033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate.
    Christensen RH; von Scholten BJ; Hansen CS; Heywood SE; Rosenmeier JB; Andersen UB; Hovind P; Reinhard H; Parving HH; Pedersen BK; Jørgensen ME; Jacobsen PK; Rossing P
    Eur J Prev Cardiol; 2017 Sep; 24(14):1517-1524. PubMed ID: 28650207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of radial pulse spectrum on the risk of major adverse cardiovascular events in patients with type 2 diabetes.
    Chang CW; Liao KM; Chang YT; Wang SH; Chen YC; Wang GC
    J Diabetes Complications; 2019 Feb; 33(2):160-164. PubMed ID: 30381150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered relation of the renin-aldosterone system and vasoactive peptides in type 2 diabetes: The KORA F4 study.
    Then C; Rottenkolber M; Lechner A; Meisinger C; Heier M; Koenig W; Peters A; Rathmann W; Bidlingmaier M; Reincke M; Seissler J
    Atherosclerosis; 2016 Sep; 252():88-96. PubMed ID: 27508320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain.
    Tzikas S; Keller T; Ojeda FM; Zeller T; Wild PS; Lubos E; Kunde J; Baldus S; Bickel C; Lackner KJ; Münzel TF; Blankenberg S
    Heart; 2013 Mar; 99(6):388-95. PubMed ID: 23213173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.